Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol - Takeaways - MDSpire

Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol

  • By

  • Jinyi Fu

  • Yifei Qi

  • Jingyi Zhan

  • Linjing Su

  • Yucong Gao

  • Qingbing Zhou

  • Ying Zhang

  • June 3, 2026

  • 0 min

Share

  • 1

    Type 2 diabetes mellitus affects over 500 million adults globally and is associated with early vascular aging, a key factor in diabetic complications.

  • 2

    The study evaluates the efficacy and safety of Yiqi-Yangyin-Huoxue granules in treating patients with type 2 diabetes and early vascular aging.

  • 3

    This randomized, double-blind, placebo-controlled trial will enroll 120 participants and assess outcomes after a 12-week intervention.

  • 4

    Primary outcomes include brachial-ankle pulse wave velocity, while secondary outcomes encompass blood glucose levels and lipid profiles.

  • 5

    The trial is registered with the International Traditional Medicine Clinical Trial Registry and aims to provide reliable evidence for YQYYHX.

Original Source(s)

Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol

  • by Jinyi Fu, Yifei Qi, Jingyi Zhan, Linjing Su, Yucong Gao, Qingbing Zhou, Ying Zhang

  • June 3, 2026

Related Content

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.